Clinical Trial Detail

NCT ID NCT02721732
Title Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

adrenocortical carcinoma

penile cancer

thymoma

carcinoma

skin squamous cell carcinoma

thyroid gland cancer

renal cell carcinoma

adrenal medulla cancer

testicular cancer

paraganglioma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.